Abstract
Background Vitiligo is a progressive depigmentation of the skin with unclear etiology. Cell-mediated immunity has been suggested to play an important role in the pathogenesis of vitiligo’s progression. Melan-A has a high affinity for specific CD8+ T cells and is one of the critical markers for detecting damage to melanocytes. Our study aims to demonstrate the differences in Melan-A expression associated with apoptosis of melanocytes in patients with segmental vitiligo (SV) and those with non-segmental vitiligo (NSV). Methods A cross-sectional study with 64 patients diagnosed with vitiligo, of whom 33 had NSV and 31 had SV. Skin biopsy and direct immunofluorescence were used to examine Melan-A, and the TUNEL staining method was performed to examine melanocyte apoptosis in both groups. Group comparisons were conducted using appropriate statistical methods. Results Melan-A expression was significantly higher in the NSV group than in the SV group, and there was a significant difference between the two groups (p=0.001). The median of melanocyte apoptosis in the NSV group was relatively higher than in the SV group, and a significant difference was found between the two groups (p=0.001). The Spearman’s rank correlation test between Melan-A expression and melanocyte apoptosis in the NSV group was 0.767 (76.7%) and showed a significant relationship (p<0.05). The same test in the SV group was 0.583 (58.3%) and showed a significant relationship (p<0.05). In both groups, the higher the Melan-A expression, the higher the melanocyte apoptosis. Conclusion Melan-A expression and melanocyte apoptosis are positively correlated. Higher Melan-A expression and melanocyte apoptosis in NSV indicates more severe vitiligo disease compared to SV.
Subject
General Pharmacology, Toxicology and Pharmaceutics,General Immunology and Microbiology,General Biochemistry, Genetics and Molecular Biology,General Medicine
Reference39 articles.
1. Clinical profile of segmental vitiligo in a group of Pakistani patients.;A Habib;Pak. Armed Forces Med. J.,2019
2. The use of Janus kinase inhibitors in vitiligo: a review of the literature.;N Relke;J. Cutan. Med. Surg.,2019
3. Biologic and targeted therapeutics in vitiligo.;P Karagaiah;J. Cosmet. Dermatol.,2022
4. Melanocyte homeostasis in vitiligo.;V Delmas;Vitiligo.,2019
5. The enigma and challenges of vitiligo pathophysiology and treatment.;Z Abdel-Malek;Pigment Cell Melanoma Res.,2020